IDEAYA Biosciences Grants Stock Options to New Employees
IDEAYA Biosciences announced on September 25, 2026, that it granted 94,000 stock options to three newly hired employees. The grants were made under the company's 2023 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
South San Francisco, CA – IDEAYA Biosciences disclosed on September 25, 2026, that its Compensation Committee granted stock options for 94,000 shares of common stock to three new employees on September 24, 2026. The options were issued as an inducement material to employment, adhering to Nasdaq Listing Rule 5635(c)(4).
The grants were made under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan. This plan is specifically designed for equity awards to individuals not previously employed by IDEAYA, or following a bona fide period of non-employment, as an incentive for them to join the company.
The stock options carry an exercise price of $36.74 per share, matching the closing price on the grant date. They have a 10-year term and will vest over four years. Vesting begins with 25% on the first anniversary of the vesting commencement date, followed by the remaining 75% vesting in equal monthly installments over the subsequent three years, contingent upon continued employment.
IDEAYA Biosciences is a precision medicine oncology company focused on discovering, developing, and commercializing targeted therapies for cancer. The company aims to deliver next-generation precision oncology treatments that are more selective, effective, and personalized.